Profile of:

Jürgen Braun


Work at the B.Franklin University Clinic in Berlin from 1985 - 2000 Prof. of Rheumatology Free University Berlin since 2000 Head of Rheumazentrum Ruhrgebiet from 1.1.2001 - 31.3.2021 Prof. of Rheumatology Ruhr University Bochum since 2004 Prof. of Rheumatology Ruhr University Bochum since 2018 (University position) Work in Berlin in private practice since 2021

Full name: Jürgen Braun

Current country: Germany

Membership level: Full

Type of membership: Advisory Board

Number of publications: 12

Correspondence on “Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial” by Molto et al. Ann Rheum Dis. 2021 Nov 1: annrheumdis-2021-221423. (2021)
https://pubmed.ncbi.nlm.nih.gov/34725049/

Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning (2021)
https://pubmed.ncbi.nlm.nih.gov/34711586/

No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’? (2021)
https://pubmed.ncbi.nlm.nih.gov/34656991/

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34534275/

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT (2021)
https://pubmed.ncbi.nlm.nih.gov/34481517/

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence (2021)
https://pubmed.ncbi.nlm.nih.gov/34471428/

Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls (2021)
https://pubmed.ncbi.nlm.nih.gov/34393107/

Development of quality standards for patients with axial spondyloarthritis for use in Germany (2021)
https://pubmed.ncbi.nlm.nih.gov/34379181/

Braun J, Baraliakos X, Kiltz U. Treat-to-target in axial spondyloarthritis – what about physical function and activity? Nat Rev Rheumatol. 2021 Sep;17(9):565-576. doi: 10.1038/s41584-021-00656-5. Epub 2021 Jul 26. PMID: 34312518. (2021)
https://pubmed.ncbi.nlm.nih.gov/34312518/

Answering epidemiologic rheumatologic questions by cooperation with the large population-based SHIP cohort-findings with relevance for the diagnosis of axial spondyloarthritis (axSpA) (2021)
https://pubmed.ncbi.nlm.nih.gov/34264363/

What’s new on the sacroiliac joint ? (2021)
https://pubmed.ncbi.nlm.nih.gov/34015085/

Response to: ‘Correspondence on ‘Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?’ by Su et al (2021)
https://pubmed.ncbi.nlm.nih.gov/34001516/